Zevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call March 9, 2026 4:30 PM EDT
Company Participants
Nichol Ochsner – Vice President of Investor Relations & Corporate Communications
Neil McFarlane – President, CEO & Director
Joshua Schafer – Chief Commercial Officer
Justin Renz – Chief Financial Officer
Conference Call Participants
Kristen Kluska – Cantor Fitzgerald & Co., Research Division
Jason Butler – Citizens JMP Securities, LLC, Research Division
Eddie Hickman – Guggenheim Securities, LLC, Research Division
Sumant Kulkarni – Canaccord Genuity Corp., Research Division
Brandon Folkes – H.C. Wainwright & Co, LLC, Research Division
Lachlan Hanbury-Brown – William Blair & Company L.L.C., Research Division
Presentation
Operator
Good afternoon, and thank you for joining Zevra’s Fourth Quarter and Full Year 2025 Financial Results and Corporate Update Conference Call. Today’s call is being recorded and will be available via the Investor Relations section of the company’s website later today. The host for today’s call is Nichol Ochsner, Zevra’s Vice President of Investor Relations and Corporate Communications.
Nichol Ochsner
Vice President of Investor Relations & Corporate Communications
Thank you, and welcome to those who are joining us. Today, we will provide an overview of our recent accomplishments, followed by a review of our fourth quarter and full year 2025 financial results. I encourage you to read the financial results news release, which was distributed this afternoon, and is available in the Investors section of our website.
Before we begin the call, please note that certain information shared today will include forward-looking statements. Actual results may differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with Zevra’s business. Forward-looking statements are not promises or guarantees and are inherently subject to risks, uncertainties and other important factors that may lead to actual results differing materially from the projections made, and should be evaluated together with the Risk Factors section in
